Matrixyl vs Palmitoyl Tetrapeptide-7
A side-by-side research comparison of Matrixyl and Palmitoyl Tetrapeptide-7 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Matrixyl | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Full name | Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS) | Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Signals through TGF-B pathway to stimulate fibroblast production of collagen I, III, IV, fibronectin, and hyaluronic acid. Palmitoyl chain enhances penetration. | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. |
| Molecular weight | 802.1 Da | 693 Da |
| Half-life | 6-12 hours (topical depot) | 8-12 hours (topical) |
| Bioavailability | Moderate (topical) | Good (topical) |
| Typical dose | 2-8% in serum/cream | 2-4% in formulation |
| Frequency | 1-2x daily | 1-2x daily |
| Route | Topical | Topical |
Matrixyl reported benefits
- Stimulates collagen I, III, IV
- Reduces wrinkle depth up to 45%
- Increases skin thickness
- Improves firmness
- Enhances hydration
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Related comparisons
Research and educational reference only. Not medical advice.